Metrics as of 10/16/2026, 01:25 PM (Berlin time), refresh in progress.
Estrella Immunopharma Stock
Estrella Immunopharma, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Cheng Liu
- Employees
- 3
- Market cap
- $19 M
- IPO
- 14/09/2021
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse…
Estrella Immunopharma stock: price history
1D
-19.7%
1W
+4.9%
1M
-32.8%
6M
-77.1%
YTD
-72.4%
1Y
-73.3%
2Y
-50.0%
5Y
-95.6%
10Y
–
Next earnings date
Next earnings date
02/12/2026 (in 46 days)
Volatility around earnings
~22% weaker price swings than usual
Ask the agents about Estrella Immunopharma
Analyst assessment of Estrella Immunopharma
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 09/02/2026
Estrella Immunopharma stock metrics
P/E
-1.75
P/B
-2.49
EV/EBITDA
-2.36
RETURN ON EQUITY
31.0%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
39.6%
FLOAT SHARES
17,216,643
AVG. DAILY VOLUME (30D)
2,990,512
Insider transactions (SEC)
Liu Cheng
Xu Jiandong
Xu Jiandong
Xu Jiandong
Xu Jiandong
Institutional holders
Comparable stocks
Frequently asked questions about Estrella Immunopharma stock
What does Estrella Immunopharma do?
Estrella Immunopharma, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Cheng Liu, the company employs around 3 people.
The IPO was on 14/09/2021; the stock trades on NASDAQ under the ticker ESLA.
What do analysts say about Estrella Immunopharma stock?
1 analysts rate the stock, the consensus is Buy (as of 09/02/2026).
This is an external assessment, not a statement by Market Jury.
When does Estrella Immunopharma report next?
The next earnings date is 02/12/2026.
Around past earnings, price swings were roughly -22% stronger than usual.
Does Estrella Immunopharma pay a dividend?
No, Estrella Immunopharma currently does not pay a dividend.
Which stocks are comparable to Estrella Immunopharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Estrella Immunopharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Estrella Immunopharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.